Hepatitis C
- PMID: 37741678
- DOI: 10.1016/S0140-6736(23)01320-X
Hepatitis C
Abstract
Hepatitis C virus (HCV) is a hepatotropic RNA virus that can cause acute and chronic hepatitis, with progressive liver damage resulting in cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In 2016, WHO called for the elimination of HCV infection as a public health threat by 2030. Despite some progress, an estimated 57 million people were living with HCV infection in 2020, and 300 000 HCV-related deaths occur per year. The development of direct-acting antiviral therapy has revolutionised clinical care and generated impetus for elimination, but simplified and broadened HCV screening, enhanced linkage to care, and higher coverage of treatment and primary prevention strategies are urgently required.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests SSS declares institutional grant support from the National Institutes of Health, Elton John AIDS foundation, US President's Emergency Plan for AIDS relief and US Agency for International Development, Gilead Sciences, and Abbott Laboratories, and honoraria from Gilead Sciences and Abbott Laboratories. NAT declares institutional grant support from the National Institutes of Health, GlaxoSmithKline, Genetech-Roche, Helio Health, Durect Corp, Gilead Sciences, and Eiger Pharmaceuticals, and consulting fees from Moderna. GJD declares institutional grant support from Gilead Sciences, AbbVie, and Merck. MM declares no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
